

The eLife article

Abstract This is the abstract. This article will describe the eLife article and the process. An abstract can contain any formatting, such as *italics*, bold, ^{superscript} or _{subscript}. MathML is also allowed: $m p^{-0}$

eLife does not structure abstracts into sub headings expect in a clinical trial article, but the abstract can have multiple paragraphs. The sub DOI is always .001 as it is the first asset in any article. I have added an unmatched > bracket as this has been an issue for PubMed deposits in the past.

If this was a clinical trial the clinical trial details would be listed at the end of the abstract:

Clinical trial Registration: EudraCT2004-000446-20.

DOI: <https://doi.org/10.7554/eLife.00666.001>

MELISSA HARRISON, JNR^{1†§¶}, JAMES F GILBERT^{1†}, ELIFE EDITORIAL PRODUCTION GROUP[‡], ELIFE TECHNOLOGY GROUP^{2‡} AND FOR THE ELIFE STAFF TEAM

***For correspondence:**

m.harrison@elifesciences.org
(MH); c.wilkinson@elifesciences.org (CW)

[†]These authors contributed equally to this work

[‡]These authors also contributed equally to this work

Present address: [§]Department of Wellcome Trust, Sanger Institute, London, United Kingdom

[#]Deceased. (not really!!)

[¶]This footnote text must work in isolation as nothing is processed on the html view to make it "work"

Group author details:

eLife Editorial Production Group
eLife Technology Group See [page 9](#)

Competing interest: See [page 9](#)

Funding: See [page 9](#)

Reviewing editor: Andrew Collings, eLife Sciences, United Kingdom

© Copyright Harrison et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Introduction (Level 1 heading)

This article is a guide to the tagging and display of eLife articles and will encompass all the elements that can possibly be contained in an eLife article. It will also include information from the author guide. For this reason, it is colloquially known as the eLife 'kitchen sink'.

The eLife editorial process (level 2 heading)

eLife publishes the most highly influential research across the life sciences and biomedicine. Before you submit your work, please note that eLife is a very selective journal that aims to publish work of the highest scientific standards and importance. Leading academic researchers evaluate new submissions and approximately two-thirds are returned to the authors without further peer review. See [DeLano, 2002](#) and [Morgan, 2016](#). Approximately half of the articles that are selected for peer review go on to be published ([Brettar et al., 2014a](#)). If other researchers publish similar findings after submission, this will not be a reason for rejection. The eLife editorial process broadly occurs in three phases ([Turlings and Wäckers, 2004](#); [Wolski et al., 2008](#); [Walker, 1995](#); [Tanaka et al., 2016](#)). If you are interested in submitting your work to eLife, please review the guidelines relating to initial submissions. If you have received an encouraging response to your initial submission, please review the guidelines relating to full submissions. If your full submission has been peer reviewed and you have been asked to make revisions, please review our guidelines for revised submissions ([Brettar et al., 2004b](#)).

Initial submission (level 3 heading)

eLife publishes research of the very highest ([Bricogne et al., 2011](#)) standard and significance, so many manuscripts are returned to the authors without in-depth peer review. During the initial submission phase, members of eLife's senior editorial team rapidly assess new submissions, often in consultation with members of the Board of Reviewing Editors or with external guest editors where necessary, to identify the ones that are appropriate for in-depth peer review ([Cardé and Millar, 2004](#); [Cartwright, 2016](#); [Chmeil, 2008](#)). To simplify the submission process, authors should submit their full manuscript as a single PDF. Limited additional information is collected via the submission screen questions to complete the submission ([Brettar et al., 2014b](#)).

Full submission (level 3 heading)

For manuscripts that are invited for in-depth peer review, see [Coyne et al., 1989](#) and [Du et al., 2014](#), we request detailed information about the work to support the peer review process, to ensure that the work meets appropriate standards for the reporting of new findings, and, if accepted, to assist in rapid publication and further dissemination of the work in relevant indexes and repositories. Authors are asked to agree to publish their work under the terms of the Creative Commons Attribution license (PDF of the agreement), or the Creative Commons CC0 public domain dedication (PDF of the agreement) if one or more authors are US-government employees ([Hubbard and Thornton, 1993](#); [GlaxoSmithKline UK, 2016](#); [Jain et al., 2010](#)).

Revised submission (level 3 heading)

We will require a response to the essential revision requirements outlined in the decision letter. A response to minor comments is optional. In the event of acceptance, the substantive revision requests and the authors' response will be published, under the terms of the Creative Commons Attribution license. In preparation for submission, authors should ensure they have all the materials and information necessary to expedite the submission and assessment of their work (Eisen, 2016; Ferry et al., 2014; Gavrillov et al., 2014; Goodstadt, 2010; Hoang et al., 2015).

The eLife production process (level 2 heading)

Immediate publication (accepted manuscript) (level 3 heading)

On acceptance an eLife article can be published in accepted manuscript form immediately. The mean time from acceptance to publication at this stage is 1 day. Using SQL, basic metadata is exported from the submission system to an AWS bucket as CSV files. The author files are exported to another AWS bucket and an eLife process generates a package of this information and the author files to deliver to the online platform, Continuum.

Publication of the full version (Version of record) (level 3 heading)

The production process includes an author proofing cycle, the output of which is the final full text version of the article online, as well as a typeset PDF.

Publication of versions (level 3 heading)

eLife allows the publication of updates to an article after the full version has been produced. These are treated as new versions of the article. All previous versions of the article will continue to exist online and will be accessible from the latest live version.

level 4 heading

eLife allows up to four levels of headings and no more. This is a demonstration of a level 4 heading.

Results

This section will be used to demonstrate the majority of eLife XML tagging and editorial policies. However, the Introduction section was used to demonstrate heading levels. See **Appendix 1** and **2**.

eLife controlled lists

eLife has no strict requirements for the display of lists. Below we will show examples of how to present lists. See **Figure 2—figure supplement 1** for

the representation of the Major Subject Areas, Research Organisms and author keywords on the eLife HTML page (**The *Shigella* Genome Sequencing Consortium, 2015a**).

Article types

This is an example of a list where the prefix character is a lowercase roman numeral. eLife Article Types are taken from a controlled list:

- i. Research article
- ii. Short Report
- iii. Tools and Resources
- iv. Research Advance
- v. Registered Report
- vi. Replication Study

Article types (XML only, not display) (level 4 heading)

This is an example of a list where the prefix character is an uppercase roman numeral. This is a controlled list from the JATS DTD

- I. article-commentary (used for Insights)
- II. correction
- III. discussion (used for Feature 1 and Feature 2)
- IV. editorial
- V. research-article (all research content)

Nested lists are allowed and these are very common in Registered Reports. Below is an example of a nested list to 3 levels.

- I. Genus: Plasmodium; following species are known to infect humans
 - i. *P. falciparum*
 - ii. *P. vivax*
 - iii. *P. ovale*
 - iv. *P. malariae*
 - v. *P. knowlesi*
- II. Genus: Leishmania. There are 3 subgenus of Leishmania:
 - i. Leishmania
 - ii. Sauroleishmania
 - iii. Viannia
 - iv. Within Viannia subgenus, there are 11 species:
 - *L. braziliensis*
 - *L. colombienseis*
 - *L. equatorensis*
 - *L. guyanensis*
 - *L. lainsoni*
 - *L. naiffi*
 - *L. panamensis*
 - *L. peruviana*
 - *L. pifanoi*
 - *L. shawi*
 - *L. utingensis*

Major Subject Areas

This is an example of a bulleted list. eLife Major subject areas are taken from a controlled list:

- Biochemistry
- Biophysics and Structural Biology
- Cell Biology
- Computational and Systems Biology
- Developmental Biology and Stem Cells
- Ecology
- Epidemiology and Global Health
- Genes and Chromosomes
- Genomics and Evolutionary Biology
- Human Biology and Medicine
- Immunology
- Microbiology and Infectious Disease
- Neuroscience
- Plant Biology

Research Organisms

This is an example of an ordered list, the "system" will default to numbers. eLife Research organisms are taken from a controlled list from the submission system:

1. *Arabidopsis*
2. *B. subtilis*
3. *C. elegans*
4. *C. intestinalis*
5. Chicken
6. *D. melanogaster*
7. *Dictyostelium*
8. *E. coli*
9. Frog
10. Human
11. *M. mulatta*
12. Maize
13. Mouse
14. *M. thermophila*
15. *M. crassa*
16. *Neurospora*
17. None
18. Other
19. *O. fasciatus*
20. *P. falciparum*
21. *P. dumerilii*
22. Rat
23. *S. cerevisiae*
24. *S. pombe*
25. *S. entericaserovar Typhi*
26. *S. pyogenes*
27. Virus
28. *Volvox*
29. *Xenopus*
30. *P. cynocephalus*
31. Zebrafish

However, additional research organisms can be added during the production process so this is not a controlled list once it is output from the editorial system. The research organism

"Other" is hidden from display on the eLife website.

Tables

This section is an example of different tables, there are four in total (**Tables 1 to 3** and an unnamed inline table).

Table 2 is an example of a standard table that will be the width of the text column in the PDF. It does not contain any unusual styling. It does have footnotes linked to content in the table using the prescribed symbols.

Table 3 is an example of a narrow table that will appear at half the text column width in the PDF. It also has source data.

The following unnamed table is an example of an inline table that has no heading.

	pY	Experiment	Concentration (μM)
IGF1R-fl + IGF1	+	K_m ATP	500, 400, 300, 250, 125, 62.5, 31.3, 15.6, 7.8
IGF1R-fl + IGF1	+	K_m Peptide	600, 300, 150, 75, 37.5, 18.8, 9.4
IGF1R-fl + IGF1	–	K_m ATP	2000, 1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8
IGF1R-fl + IGF1	–	K_m Peptide	500, 250, 125, 62.5, 31.3, 15.6, 7.8, 3.9
IGF1R-fl	+	K_m ATP	500, 400, 300, 250, 125, 62.5, 31.3, 15.6, 7.8
IGF1R-fl	+	K_m Peptide	500, 400, 250, 125, 62.5, 31.3, 15.6, 7.8
IGF1R-fl	–	K_m ATP	1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8
IGF1R-fl	–	K_m Peptide	1000, 500, 250, 125, 62.5, 31.3, 15.6
IGF1R-icd	+	K_m ATP	500, 250, 125, 62.5, 31.3, 15.6, 7.8, 3.9
IGF1R-icd	+	K_m Peptide	1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8
IGF1R-icd	–	K_m ATP	1000, 500, 250, 125, 62.5, 31.3
IGF1R-icd	–	K_m Peptide	1000, 500, 250, 125, 62.5, 31.3
IGF1R-kin	–	K_m Peptide	1250, 625, 312.5, 156.3, 78.1, 39.1

This is an unmarked footnote for an anchored/inline table

Math

Content can contain inline formulae or display formulae. Below is an example of a mixture of inline and display formula. MathML is used in all instances.

We propose a Bayesian scheme for BCV (see **equation 1**) that accommodates the influence of context on incentive value. BCV focuses on

Table 1. This is the title.
This is the caption: A table containing interesting formatting that is large enough to require landscape orientation in the PDF.

Genotype	GLVs (percent IS plant ⁻¹)				TPS10 products (percent IS plant ⁻¹)				Non-target volatiles (percent IS plant ⁻¹)			
	Day	Night	n	Day	Night	Day	Night	Day	Night	Day	Night	Day
WT	8	8	0.99% ± 0.99%	7.96% ± 4.25%	0.37% ± 0.29%	a	—	—	a	2.13% ± 0.85%	0.96% ± 0.42%	1.68% ± 0.98%
TPS10	7	7	2.37% ± 1.55%	2.84% ± 0.63%	18.97% ± 6.03%	b	0.94% ± 0.53%	9.34% ± 3.44%	b	0.20% ± 0.20%	0.94% ± 0.26%	2.78% ± 1.52%
lox2/3	7	8	0.13% ± 0.13%	1.06% ± 0.64%	—	a	0.15% ± 0.15%	—	a	—	1.12% ± 0.60%	1.68% ± 1.49%
lox2/3;TPS10	7	7	0.07% ± 0.07%	1.24% ± 0.84%	7.39% ± 2.56%	b	2.08% ± 0.84%	4.47% ± 1.70%	b	0.40% ± 0.40%	0.73% ± 0.31%	0.66% ± 0.37%

Footnotes not linked to content within the table text are usually to define abbreviations. For example:
WT, wild type.
DOI: <https://doi.org/10.7554/eLife.00666.003>

Table 2. This table contains references and footnotes and is sized to the text column width in the PDF.

Protein	Molar ratio of lipid:protein in RPL reactions*	Molar ratio of lipid:protein on vacuoles		References†
		BJ3505	DKY6218	
Vam7p	2 × 10 ³	30 × 10 ⁴	6.5 × 10 ⁴	DeLano, 2012
Vam3p	2 × 10 ³	11 × 10 ⁴	22 × 10 ⁴	Morgan, 2016
Vti1p	2 × 10 ³	10 × 10 ⁴	13 × 10 ⁴	Zhong et al., 2013
Nyv1p	2 × 10 ³	4.3 × 10 ⁴	8.1 × 10 ⁴	Ferry et al., 2014
Ypt7p	4 × 10 ³	1.9 × 10 ⁴	1.8 × 10 ⁴	Zhong et al., 2013
Sec17p	7 × 10 ³	41 × 10 ⁴	13 × 10 ⁴	Wolski et al., 2008
Sec18p	1 × 10 ³	10 × 10 ⁴	13 × 10 ⁴	This article (Figure 1)
Vps33p	6 × 10 ³	17 × 10 ⁴	31 × 10 ⁴	Zhong et al., 2013

*Footnotes can be used to highlight properties of data reported in a table such as statistical significance. They are separate from the table caption and appear afterwards. They are hyperlinked to allow easy navigation. Footnotes in tables use the same standard set of symbols used for authors footnotes.

†Authors are fully allowed to cite references and figures in tables. There is no difference in citation style between the main text and tables.

Order: Designated footnotes (e.g. *, †, ‡, §, #, ¶, **, and so on), p value footnotes (*p, **p, ***p), undesigned footnotes and abbreviations.

DOI: <https://doi.org/10.7554/eLife.00666.004>

scenarios (i) where incentive value depends on contextual information (either represented by cues or by previous rewards) provided before options or rewards are presented, and (ii) where reward is defined by a single attribute (e.g., reward amount). To describe the basic principles of BCV, we adopt the formalism of Bayesian graphs (The *Shigella* Genome Sequencing Consortium, 2015c) where a generative model is described by nodes or circles, representing random variables (shaded and white circles refer to observed and non-observed variables respectively), and arrows, representing

causal relationships among variables. A simple generative model hypothesized by BCV is shown in Figure 1A of another article (not linked here), where C represents prior beliefs about the average reward expected in a given context. Formally, this corresponds to a (Gaussian) prior belief (with mean μ_c and variance σ_c^2 over the mean of a (Gaussian) distribution of reward options R (with variance σ_R^2). When R is observed, a posterior expectation about the context is obtained by application of Bayes rule (The *Shigella* Genome Sequencing Consortium, 2015b):

$$\mu_{C|R} = \mu_C + \frac{\sigma_C^2}{\sigma_C^2 + \sigma_R^2} (R - \mu_C)$$

(1)

Figures

This section of the article shows how figures should be presented and will include examples of single figures and figures arranged with a variety of additional assets.

Figure 1 is an example of a single figure.

Figure 2 is an example of a figure with figure supplements, Figure 2—figure supplement 1 and Figure 2—figure supplement 2.

Figure 3 is an example of a figure with a figure supplement (Figure 3—figure supplement 1) with two sub-assets, Figure 3—figure supplement 1—Source data 1 and Figure 3—figure supplement 1—Video 1 (see Zhong et al., 2013; World Health Organization, 2016).

Figure 4 is an example of a figure with source code (Figure 4—Source code 1).



Figure 1. Single figure: The header of an eLife article example on the HTML page. For the purpose having an example of how to tag a separate license for an item, we have indicated in the XML and display this is a copyrighted figure; however it is not. © 2016 eLife. All rights reserved. DOI: <https://doi.org/10.7554/eLife.00666.007>

Table 3.

Data collection	
Space group	P6 ₂
Cell dimensions (Å)	a = b = 78.33, c = 62.32
	$\alpha = \beta = 90^\circ, \gamma = 120^\circ$
Wavelength (Å)	0.9794
R _{sym} or R _{merge} (%)	8.4
Resolution (Å)	50–2.05 (2.09–2.05)
I/σI	19.19 (3.23)
Completeness (%)	99.8 (97.3)
Redundancy	6.2 (5.4)
Refinement	
No. reflections	12,206
Resolution (Å)	39.17–2.06 (2.14–2.06)
R _{work} /R _{free}	0.17/0.21 (0.16/0.19)
No. atoms	
Protein	1608
Ligand/ion	3
Water	61
R.m.s. deviations	
Bond lengths (Å)	0.0077
Bond angles (°)	0.932

DOI: <https://doi.org/10.7554/eLife.00666.005>

The following source data available for Table 3:

Source data 1. Representative curves of steady-state kinetic analyses for each IGF1R protein characterized. Each data point was performed in duplicate and is shown separately.

DOI: <https://doi.org/10.7554/eLife.00666.006>



Video 1. A description of the eLife editorial process.

DOI: <https://doi.org/10.7554/eLife.00666.015>

The following source data is available for video 1:

Video 1—Source data 1. Title of the source code.

DOI: <https://doi.org/10.7554/eLife.00666.036>



Figure 2. Figure with figure supplementThis is the basic infomration provided about an article. **Figure 1** shows an expanded view (Kok et al., 2015; National Institute of Mental Health, 1990) DOI: <https://doi.org/10.7554/eLife.00666.008> The following figure supplements are available for figure 2:

Figure supplement 1. The representation of the Major Subject Areas, Research Organisms and author keywords on the eLife HTML page DOI: <https://doi.org/10.7554/eLife.00666.009> **Figure supplement 2.** Representation of figure with figure supplements on the HTML view. DOI: <https://doi.org/10.7554/eLife.00666.010>

Videos

Video 1 shows the editorial process.

Other stuff

Boxes

It is rare for eLife research articles to contain boxes; however they are common in Feature content. **Box 1** is a simple box that contains very little text and **Box 2** is larger.

RRIDs

If an author mentions an RRID in their content, it is required that we link it, for example, **RRID:** [IMSR_JAX:004435](#).

Coloured text

Here is an example of making text display in different colours: **Blue text:** #366BFB; **Purple text:** #9C27B0; and **Red text:** #D50000.

Inline graphics

Here is an example of pulling in an inline graphic




Figure 3. Figure with figure supplements and figure supplement with source data and a video (see *Koch, 1959*).

DOI: <https://doi.org/10.7554/eLife.00666.011>

The following source data and figure supplements are available for figure 3:

Figure 3—figure supplement 1. Title of the figure supplement

DOI: <https://doi.org/10.7554/eLife.00666.012>

Figure 3—figure supplement 1—Source data 1. Title of the figure supplement source data.

DOI: <https://doi.org/10.7554/eLife.00666.013>

Figure 3—Video 1. A description of the eLife editorial process.

DOI: <https://doi.org/10.7554/eLife.00666.035>




Figure 4. Single figure with source code.

DOI: <https://doi.org/10.7554/eLife.13222.014>

The following source code is available for figure 4:

Source code 1. Title of the source code.

DOI: <https://doi.org/10.7554/eLife.00666.015>

Box 1. Example of a small box

Donec rhoncus in odio non vulputate. Donec vitae enim at erat tincidunt tincidunt in nec arcu. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Aliquam id nunc id arcu maximus rutrum. Praesent bibendum nisl orci, ac sollicitudin purus aliquam in. Duis eu fermentum arcu. Fusce eget dolor augue. Nulla facilisi. Suspendisse eu nisl vitae neque ullamcorper imperdiet. (see **Nellåker, 2014**; **Pages et al., 2014**; and **Palmer et al., 2007**) Vestibulum ultrices vehicula nibh, a ullamcorper dui semper suscipit. Etiam in sem augue.

Additional files

All files attached to an article must be cited in the main text as well. So, **Supplementary file 1** and **Source data 1** have to be cited in the text.

References


All references have to be cited in the main text. They are listed in the reference list in alphabetical order, however, in the text the citations do not have to be in the same order as they are listed according to when the author of the article cites them. This article is littered with citations to ensure all the references are cited at some point. They have no relevance to the content **Aivazian et al., 2006**.

Discussion

The function of the Discussion is to interpret your results in light of what was already known about the subject of the investigation, and to explain our new understanding of the problem after

Box 2. Example of a large box

This box contains a **figure**. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque vel rhoncus lorem. Suspendisse posuere non enim vel tempor. Fusce quis sem sed nulla tincidunt faucibus. Vivamus dictum magna in ante porttitor faucibus. Aenean lobortis, sem in viverra dignissim, odio purus vestibulum libero, in eleifend lacus metus id tortor. Phasellus tincidunt ipsum ut ornare hendrerit. Praesent lobortis consectetur egestas. Curabitur viverra lectus eu venenatis sagittis. Aliquam lobortis metus mauris, in tincidunt diam ullamcorper ac. Phasellus sagittis, leo eget lacinia commodo, eros justo mattis eros, quis dapibus ipsum ex sit amet sapien. Quisque consequat arcu ut efficitur tincidunt. Ut convallis, ex maximus aliquam tempor, lorem elit fermentum ipsum, nec volutpat velit sem a lectus. Morbi sed mauris vel purus interdum consectetur dapibus vel velit. Nam pellentesque, ipsum vel euismod mattis, turpis augue mattis nunc, ac aliquam dolor massa non mi. Vestibulum sit amet elit a augue semper facilisis interdum quis nibh. Mauris consectetur nisi aliquam urna lobortis, eu efficitur nisl lobortis; **Bates et al., 2016** and **Patterson et al., 2011**.



Name	Date Modified	Size	Kind
eLife-00666-app1-fig1-figure1.jpg	Tuesday, 10/21	5 KB	JPG image
eLife-00666-app1-fig1-figure1.png	Tuesday, 10/21	5.1 KB	PNG image
eLife-00666-app1-media1.mp4	Tuesday, 10/21	20.6 KB	MP4 video
eLife-00666-data1.xlsx	Tuesday, 10/21	23 KB	Microsoft Excel spreadsheet
eLife-00666-fig1-v1.pdf	Tuesday, 10/21	2.1 KB	PDF image
eLife-00666-fig1-figure1-v1.pdf	Tuesday, 10/21	202 KB	PDF image
eLife-00666-fig2-figure2-v1.pdf	Tuesday, 10/21	789 KB	PDF image
eLife-00666-fig2-v1.pdf	Tuesday, 10/21	2 KB	PDF image
eLife-00666-fig3-figure3-v1.pdf	Tuesday, 10/21	188.3 KB	PDF image
eLife-00666-fig3-figure3-v1.pdf	Tuesday, 10/21	2.9 KB	PDF image
eLife-00666-fig3-v1.pdf	Tuesday, 10/21	5.9 KB	PDF image
eLife-00666-fig4-figure4-v1.pdf	Tuesday, 10/21	408 KB	PDF image
eLife-00666-fig4-v1.pdf	Tuesday, 10/21	4.1 KB	PDF image
eLife-00666-fig5-figure5-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig5-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig6-figure6-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig6-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig7-figure7-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig7-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig8-figure8-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig8-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig9-figure9-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig9-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig10-figure10-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig10-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig11-figure11-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig11-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig12-figure12-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig12-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig13-figure13-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig13-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig14-figure14-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig14-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig15-figure15-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig15-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig16-figure16-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig16-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig17-figure17-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig17-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig18-figure18-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig18-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig19-figure19-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig19-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig20-figure20-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig20-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig21-figure21-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig21-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig22-figure22-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig22-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig23-figure23-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig23-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig24-figure24-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig24-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig25-figure25-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig25-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig26-figure26-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig26-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig27-figure27-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig27-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig28-figure28-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig28-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig29-figure29-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig29-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig30-figure30-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig30-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig31-figure31-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig31-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig32-figure32-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig32-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig33-figure33-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig33-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig34-figure34-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig34-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig35-figure35-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig35-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig36-figure36-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig36-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig37-figure37-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig37-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig38-figure38-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig38-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig39-figure39-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig39-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig40-figure40-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig40-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig41-figure41-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig41-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig42-figure42-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig42-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig43-figure43-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig43-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig44-figure44-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig44-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig45-figure45-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig45-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig46-figure46-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig46-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig47-figure47-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig47-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig48-figure48-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig48-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig49-figure49-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig49-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig50-figure50-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig50-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig51-figure51-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig51-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig52-figure52-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig52-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig53-figure53-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig53-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig54-figure54-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig54-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig55-figure55-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig55-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig56-figure56-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig56-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig57-figure57-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig57-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig58-figure58-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig58-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig59-figure59-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig59-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig60-figure60-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig60-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig61-figure61-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig61-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig62-figure62-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig62-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig63-figure63-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig63-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig64-figure64-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig64-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig65-figure65-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig65-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig66-figure66-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig66-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig67-figure67-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig67-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig68-figure68-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig68-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig69-figure69-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig69-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig70-figure70-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig70-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig71-figure71-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig71-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig72-figure72-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig72-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig73-figure73-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig73-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig74-figure74-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig74-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig75-figure75-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig75-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig76-figure76-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig76-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig77-figure77-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig77-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig78-figure78-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig78-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig79-figure79-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig79-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig80-figure80-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig80-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig81-figure81-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig81-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig82-figure82-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig82-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig83-figure83-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig83-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig84-figure84-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig84-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig85-figure85-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig85-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig86-figure86-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig86-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig87-figure87-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig87-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig88-figure88-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig88-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig89-figure89-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig89-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig90-figure90-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig90-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig91-figure91-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig91-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig92-figure92-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig92-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig93-figure93-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig93-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig94-figure94-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig94-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig95-figure95-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig95-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig96-figure96-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig96-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig97-figure97-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig97-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig98-figure98-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig98-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig99-figure99-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig99-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig100-figure100-v1.pdf	Tuesday, 10/21	47 KB	PDF image
eLife-00666-fig100-v1.pdf	Tuesday, 10/21	47 KB	PDF image

taking your results into consideration. The Discussion will always connect to the Introduction by way of the question(s) or hypotheses you posed and the literature you cited, but it does not simply repeat or rearrange the Introduction. Instead, it tells how your study has moved us forward from the place you left us at the end of the Introduction (*Schneider, 2006; Schwartz, 1993*).

Materials and methods

eLife is tagged up as XML using the NISO standard JATS DTD. We conform to the JATS4R recommendations where possible and also deliver our content to PMC. We also convert our JATS XML to PubMed and CrossRef DTDs when we deposit our content with them. eLife content is delivered to more repositories and it can be scraped from the eLife site (*Gall et al., 2012; Horne and Page, 2008; McQuilton et al., 2012; Staab et al., 2013*).

The following is an example of monotype text within the body of an eLife article.

```
PNRE+AP-1: 5' - CTTCGTGACTAGTCTTGACT-
CAGA -3'
PRAM: 5' - CTAGAAGTTTGTTCGTGACTCAGA -3'
E1: 5' - CTAGAAGTTTGTTCGTGACTCAGCCGA -3'
E2: 5' - CTAGAAGTTTGTTCGTGACTCATTAGA -3'
E3: 5' - CTAGAAGTTTGTGTATGACTCAGA -3'
CME: 5' - CTAGAAATTTGTACGTGCCACAGA -3'
```

Acknowledgements

We thank JATS4R, Exeter Premedia and PMC for their contributions.

Melissa Harrison Jnr Department of Production, eLife, Cambridge, United Kingdom
 <http://orcid.org/0000-0003-3523-4408>

James F Gilbert Department of Production, eLife, Cambridge, United Kingdom

eLife Editorial Production Group

Writing group



Alistair Shearer: eLife, Cambridge, United Kingdom; **Hannah Caton:** eLife, Cambridge, United Kingdom; eLife Institute, Cambridge, United Kingdom


Editing group

Wei Mun Chan: eLife, Cambridge, United Kingdom; **Hannah Drury:** eLife, Cambridge, United Kingdom; **Maria Guerreiro:** eLife, Cambridge, United Kingdom; **Susanna Richmond:** eLife, Cambridge, United Kingdom for the eLife Staff Team

eLife Technology Group

Nott Graham: Graham Nott Enterprises, Victoria, Canada; **Wilkinson Chris:** eLife, Cambridge, United Kingdom,  <http://orcid.org/0000-0003-4921-6155>; **Skibinski Luke:** eLife, Cambridge, United Kingdom

Author contributions: Melissa Harrison, Completed the XML mapping exercise and wrote this XML example; James F Gilbert, Contributed to the XML mapping exercise and  checked all the tagging and content; Chris Wilkinson, Performed the XML mapping exercise and generated the JSON Schema; Graham Nott, Wrote the JATSscraper; Luke Skibinski, Identified missing components from the JATSscraper; eLife Editorial Production .

Competing interests:  Melissa Harrison: Chair of JATS4R; Graham Nott is not an eLife employee; The other authors declare that no competing interests exist.

Received 01 March 2016

Accepted 01 April 2016

Published 25 April 2016

Ethics: Human subjects: If Research Ethics Committee and Institutional Review Board approval was required for this article the details would be listed here.

Animal subjects: If there were animal subjects involved in the study the approval number for the research along with protocol approval would be listed here.

If this article was part of a clinical trial the Clinical trial registry and ID would be listed here, for example:

Clinical trial Registry: EudraCT.

Registration ID: EudraCT2004-000446-20.

Funding

Funder	Grant reference number	Author
Howard Hughes Medical Institute	F32 GM089018	Melissa Harrison

The funders had no role in study design; collection, analysis, and interpretation of data; writing the article; and or the decision to submit to the journal.

Decision letter and Author response

Decision letter DOI: <https://doi.org/10.7554/eLife.00666.029>

Author response DOI: <https://doi.org/10.7554/eLife.00666.030>

Additional files

Supplementary files

- Supplementary file 1. This is the title of the supplementary file 1. A file containing underlying data.

DOI: <https://doi.org/10.7554/eLife.00666.019>

- Source data 1. This is the title of the source data that is not attached to a specific figure, but to the article as a whole.

DOI: <https://doi.org/10.7554/eLife.00666.020>

- Source code 1. This is the title of the source code that is not attached to a specific figure, but to the article as a whole.

DOI: <https://doi.org/10.7554/eLife.00666.021>

- Reporting Standard 1. CONSORT flow diagram.

DOI: <https://doi.org/10.7554/eLife.00666.022>

Major datasets

The following dataset was generated:

Author(s)	Year	Dataset URL	Database, license, and accessibility information
Harrison MYork University	2016	https://github.com/elifesciences/XML-mapping/blob/master/elife-00666.xml	Publicly available on GitHub

The following previously published datasets were used:

Author(s)	Year	Dataset URL	Database, license, and accessibility information
M Harrison	2012	https://github.com/elifesciences/elife-vendor-workflow-config	Publicly available on GitHub.
Kok K, Ay A, Li L, Arnosti DN	2015	Data from: Genome-wide errant targeting by Hairy	Dryad Digital Repository https://doi.org/10.5061/dryad.cv323

References

Aivazian D, Serrano RL, Pfeffer S. 2006. TIP47 is a key effector for Rab9 localization. *The Journal of Cell Biology* **173**:917–926. doi: <https://doi.org/10.1083/jcb.200510010>, 16769818

Bates D, Maechler M, Bolker B, Walker S, Haubo Bojesen Christensen R, Singmann H, Dai B, Grothendieck G, Green P., Bolker B. 2016. lme4: Linear Mixed-Effects Models Using Eigen and S4. CRAN. 1.1-12. <https://cran.r-project.org/web/packages/lme4/index.html>.

Bloss CS, Wineinger NE, Peters M, Boeldt DL, Ariniello L, Kim JL, Judy Sheard J, Komatireddy R, Barrett P, Topol EJ. 2016. A prospective randomized trial examining health care utilization in individuals using multiple smartphone-enabled biosensors. *bioRxiv*. doi: <https://doi.org/10.1101/029983>

Bouveret R, Waardenberg AJ, Schonrock N, Ramialison M, Doan T, de Jong D, Bondue A, Kaur G, Mohamed S, Fonoudi H, Chen C, Wouters M, Bhattacharya S, Plachta N, Dunwoodie SL, Chapman G, Blanpain C, Harvey RP. 2015. NKX2-5 mutations causative for congenital heart disease retain functionality and are directed to hundreds of targets. *NCBI Gene Expression Omnibus*. **GSE44902**. **Brettar I**, Christen R, Höfle MG. 2004a. Aquiflexum balticum gen. nov., sp. nov., a novel marine bacterium of the Cytophaga-Flavobacterium-Bacteroides group isolated from surface water of the central Baltic Sea. *International Journal of Systematic and Evolutionary Microbiology* **54**:2335–2341. doi: <https://doi.org/10.1099/ijs.0.63255-0>, 15545480

Brettar I, Christen R, Höfle MG. 2004b. Belliella baltica gen. nov., sp. nov., a novel marine bacterium of the Cytophaga-Flavobacterium-Bacteroides group isolated from surface water of the central Baltic Sea. *International Journal of Systematic and Evolutionary Microbiology* **54**:65–70. doi: <https://doi.org/10.1099/ijs.0.02752-0>, 14742460

Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P, Paciorek W, Roversi P, Sharff A, Smart OS, Vornrhein C, Womack TO. 2011. BUSTER. 2.10.0. Cambridge, UK: Global Phasing Ltd. <https://www.globalphasing.com/buster/>.

Cardé R. T, Millar J. G (Eds). 2004. *Advances in Insect Chemical Ecology*. Cambridge: Cambridge University Press.

Cartwright A. 2016. The Venus Hypothesis. *arXiv.org*. <https://arxiv.org/abs/1608.03074>.

Chmiele N. 2008. 2nd edn. *An Introduction to Work and Organizational Psychology: A European Perspective*. Wiley-Blackwell.

Coyne JA, Orr HA. 1989. Two rules of speciation. In: Otte D, Endler J. A (Eds). *Speciation and Its Consequences*. Sunderland, MA: Sinauer Associates.

DeLano W. 2002. The PyMol Molecular Graphics System. PyMol. Version 1.7.4. Schrödinger LLC. <https://www.pymol.org/>.

Du J, Johnson LM, Groth M, Feng S, Hale CJ, Li S, Vashisht AA, Gallego-Bartolome J, Wohlschlegel JA, Patel DJ, Jacobsen SE. 2014. Crystal structure of KRYPTONITE in complex with mCHH DNA and SAH. *RCSB Protein Data Bank*. RCSB Protein Data Bank. doi: <https://doi.org/10.2210/pdb4qen/pdb>

EisenM. 2016. The Imprinter of All Maladies. *it is NOT junk*. <http://www.michaeliseisen.org/blog/?p=1894> [Accessed August 8, 2016].

Ferry Q, Steinberg J, Webber C, FitzPatrick DR, Ponting CP, Zisserman A, Nellåker C. 2014. Diagnostically relevant facial gestalt information from ordinary photos database. *Division of Clinical Neurology, University of Oxford*. <https://github.com/>

ChristofferNellaker/Clinical_Face_Phenotype_Space_Pipeline.

Gall A, Treuting P, Elkon KB, Loo YM, Gale M Jr, Barber GN. 2012. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. *Immunity* **36**:120–131. doi: <https://doi.org/10.1016/j.immuni.2011.11.018>, 22284419

Gavrilov S, Harvey RP, Papaioannou VE. 2014. Mus musculus T-box 2 (Tbx2), mRNA. *NCBI Nucleotide*. [NM_009324](https://www.ncbi.nlm.nih.gov/nuccore/NM_009324). [NM_009324.2](https://www.ncbi.nlm.nih.gov/nuccore/NM_009324.2).

GlaxoSmithKline UK. 2016. *Augmentin 250/62 SF Suspension*. United Kingdom: GlaxoSmithKline UK. <https://www.medicines.org.uk/emc/medicine/19188>.

Goodstadt L. 2010. Ruffus: a lightweight Python library for computational pipelines. *Bioinformatics* **26**: 2778–2779. doi: <https://doi.org/10.1093/bioinformatics/btq524>, 20847218

Hoang C, Swift GH, Azevedo-Pouly A, MacDonald RJ. 2015. Effects on the transcriptome of adult mouse pancreas (principally acinar cells) by the inactivation of the Ptf1a gene in vivo. *NCBI Gene Expression Omnibus*. [GSE70542](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70542).

Horne P, Page J. 2008. *Integrated Pest Management for Crops and Pastures*. Victoria: Landlinks Press. 9780643092570

Hubbard S, Thornton J. 1993. Naccess. Department of Biochemistry Molecular Biology, University College London. V2.1.1. <http://www.bioinf.manchester.ac.uk/naccess>.

Jain BV, Bollman B, Richardson M, Berger DR, Helmstaedter MN, Briggman KL, Denk W, Bowden JB, Mendenhall JM, Abraham WC, Harris KM, Kasthuri N, Hayworth KJ, Schalek R, Tapia JC, Lichtman JW, Seung HS. 2010. Boundary learning by optimization with topological constraints. IEEE Conference on Computer Vision and Pattern Recognition (CVPR), 2010.

Koch S. 1959. *Psychology a Study of a Science*. **3: Formulations of the Person and the Social Context**. McGraw-Hill Book Company.

Kok K, Ay A, Li L, Arnosti DN. 2015. Data from: Genome-wide errant targeting by Hairy. *Dryad Digital Repository*. doi: <https://doi.org/10.5061/dryad.cv323>.

McQuilton P, St Pierre SE, Thurmond J, FlyBase Consortium. 2012. FlyBase 101—the basics of navigating FlyBase. *Nucleic Acids Research* **40**:D706–D714. doi: <https://doi.org/10.1093/nar/gkr1030>, 22127867

Morgan N, Department of Education. 2016. *Educational excellence everywhere*. United Kingdom: Her Majesty's Stationery Office. 9781474130158.

National Institute of Mental Health. 1990. *Clinical training in serious mental illness (DHHS Publication No. ADM 90-1679)*. Washington, DC, United States: Government Printing Office.

Nellaker C. 2014. *Clinical_Face_Phenotype_Space_Pipeline*. Github. v1.2. https://github.com/ChristofferNellaker/Clinical_Face_Phenotype_Space_Pipeline.

Pages H, Gentleman R, Aboyoun P, Biostrings DS. 2014. String objects representing biological sequences, and matching algorithms. *Bioconductor*. R Package Version 2.30.1. <https://bioconductor.org/packages/release/bioc/html/Biostrings.html>.

Palmer JA, Kreutz-Delgado K, Rao BD, Makeig S. 2007. Probabilistic Formulation of Independent Vector Analysis Using Complex Gaussian Scale Mixtures. *Independent component analysis and signal*

separation. 8th International Conference, ICA 2009, Paraty, Brazil, March 15–18, 2009. p.90–97.

Patterson JB, Lonergan DG, Flynn GA, Qingpeng Z, Pallai PV, Mankind Corp. 2011. IRE-1alpha inhibitors. *United States patent*. US20100941530. <http://europepmc.org/patents/PAT/US2011065162>.

R Development Core Team. 2015. R: a language and environment for statistical computing. 3.2.2. Vienna, Austria: R Foundation for Statistical Computing. <http://www.r-project.org/>.

Radoshevich L, Impens F, Ribet D, Quereda JJ, Nam Tham T, Nahori MA, Bierre H, Dussurget O, Pizarro-Cerdá J, Knobeloch KP, Cossart P. 2015a. ISG15 counteracts *Listeria monocytogenes* infection. *ProteomeXchange*. [PXD001805](https://www.ebi.ac.uk/ProteomeXchange/entry/PXD001805).

Radoshevich L, Impens F, Ribet D, Quereda JJ, Nam Tham T, Nahori MA, Bierre H, Dussurget O, Pizarro-Cerdá J, Knobeloch KP, Cossart P. 2015b.

Transcription profiling by high throughput sequencing of LoVo cells infected with *Listeria* for 24 hr compared to uninfected cells. *ArrayExpress*. [E-MTAB-3649](https://www.ebi.ac.uk/ArrayExpress/entry/E-MTAB-3649).

Rasband WS. 1997. Image J. Bethesda, MA: US National Institutes of Health. <http://imagej.nih.gov/ij/>

Roy S, Wapinski, Pfiffner J, French C, Socha A, Konieczka J, Regev A. 2013. Arboretum: reconstruction and analysis of the evolutionary history of condition-specific transcriptional modules. *Genome Research*. in press. doi: <https://doi.org/10.1101/gr.146233.112>

Schneider P. 2006. PhD thesis: Submicroscopic *Plasmodium falciparum* gametocytaemia and the contribution to malaria transmission. Nijmegen, The Netherlands: Radboud University Nijmegen Medical Centre.

Schrödinger LLC. 2011. *The PyMOL Molecular Graphics System* Schrödinger LLC. 1.2r3pre. <https://www.pymol.org/>.

Schwartz J. September 9, 1993. Obesity affects economic, social status. *The Washington Post*. p. A1–A4.

Scripps Translational Science Institute. 2015. Scripps Wired for Health Study. <https://clinicaltrials.gov/ct2/show/NCT01975428>.

Smit A, Hubley R. 2010. RepeatModeler. open-1.0. Seattle, USA: Institute for Systems Biology. <http://www.repeatmasker.org/RepeatModeler.html>.

Staab TA, Griffen TC, Corcoran C, Evgrafov O, Knowles JA, Sieburth D. 2013. SKN-1 from the JASPAR CORE database. *JASPAR*. [MA0547.1](https://jaspar.genie.ucl.ac.uk/MA0547.1).

Tanaka Y, Hosoyama T, Mikamo A, Kurazumi H, Nishimoto A, Ueno K, Shirasawa B, Hamano K. 2016. Hypoxic Preconditioning of Human Cardiosphere-derived Cell Sheets Enhances Cellular Functions via Activation of the PI3K/Akt/mTOR/HIF-1α Pathway. *preprints*. doi: <https://doi.org/10.20944/preprints201608.0124.v1>

The Shigella Genome Sequencing Consortium. 2015a. Global Diversity of Shigella Species. *NCBI BioProject*. [PRJEB2846](https://www.ncbi.nlm.nih.gov/bioproject/PRJEB2846).

The Shigella Genome Sequencing Consortium. 2015b. Shigella sonnei and flexneri from around the world. *NCBI BioProject*. [PRJEB2460](https://www.ncbi.nlm.nih.gov/bioproject/PRJEB2460).

The Shigella Genome Sequencing Consortium. 2015c. Shigella flexneri from around the world. *NCBI BioProject*. [PRJEB2542](https://www.ncbi.nlm.nih.gov/bioproject/PRJEB2542).

Turlings TCJ, Wäckers FL. 2004. Recruitment of predators and parasitoids by herbivore-injured plants.

In: Cardé R. T, Millar J. G (Eds). *Advances in Insect Chemical Ecology*. Cambridge: Cambridge University Press. p. 21–75.

Walker J. 1995. Solar System Live. <https://www.fourmilab.ch/solar/>.

Wolski SC, Kuper J, Hanzelmann P, Truglio JJ, Croteau DL, Van Houten B. 2008. Crystal structure of the FeS cluster-containing nucleotide excision repair helicase XPD. *PLoS Biology* **6**:e149. doi: <https://doi.org/10.1371/journal.pbio.0060149>, 18578568

World Health Organization. 2016. 2nd edn. *Growing Up Unequal: Gender and Socioeconomic Differences*

in Young People's Health and Well-Being. Health Behaviour in School-Aged Children (HBSC) Study. World Health Organization.


Zhang YA, Salinas I, Li J, Parra D, Bjork S, Xu Z, LaPatra SE, Bartholomew J, Sunyer JO. 2010. Polymeric immunoglobulin receptor [Oncorhynchus mykiss]. NCBI. [GenBank: ADB81776.1](https://www.ncbi.nlm.nih.gov/genbank/ADB81776.1).

Zhong M, Snyder M, Slightam C, Kim S, Murray J, Waterston R, Gerstein M, Niu W, Janette J, Raha D, Agarwal A, Reinke V, Sarov M, Hyman A. 2013. ChIP-Seq Identification of *C. elegans* TF Binding Sites. *modMine*. [modENCODE_3369](https://modmine.org/modENCODE_3369).

Appendix 1

Preparation

In order to prepare for this Kitchen sink we reviewed our archive and found common errors or miscommunication from the archive, tagging of **Appendix 1—Figure 1** is a classic example and here the tagging is updated. Appendices figures can also have figure supplements, for example **Appendix 1—Figure 1—Figure Supplement 1** (Koch, 1959).



Appendix 1—Figure 1. Appendix figure title. If there is a caption to accompany the title it would display here (Koch, 1959).

DOI: <https://doi.org/10.7554/eLife.00666.024>

The following figure supplement is available for figure app11:

Appendix 1—Figure 1 supplement 1. Appendix figure supplement title.

DOI: <https://doi.org/10.7554/eLife.00666.025>

Sub heading 1

This is the text of the content of subheading 1 within appendix 2.

Sub heading 2

This is the text of the content of subheading 2 within appendix 2.

Appendix 2

Negotiation

Generating the new rules involved negotiation with various vendors and downstream hosts to ensure display would work for all instances. See **Appendix 2—Video 1** and **Appendix 2—Table 1**.



Appendix 2—Video 1. A description of the eLife editorial process.

DOI: <https://doi.org/10.7554/eLife.00666.027>

Appendix 2—Table 1. Appendix table.

Name	Units	Value
E_{AMPA}	mV	0
τ_{AMPA}	ms	1
E_{NMDA}	mV	0
τ_{NMDA}	ms	100

DOI: <https://doi.org/10.7554/eLife.00666.028>